Pathologic features of prostate cancer found at population-based screening with a four-year interval

BACKGROUND: The currently recommended frequency for prostate-specific antigen (PSA) screening tests for prostate cancer is 1 year, but the optimal screening interval is not known. Our goal was to determine if a longer interval would compromise the detection of curable prostate cancer. METHODS: A cohort of 4491 men aged 55-75 years, all participants in the Rotterdam section of the European Randomized Study of (population-based) Screening for Prostate Cancer, were invited to participate in an initial PSA screening. Men who received that screening were invited for a second screen 4 years later. P... Mehr ...

Verfasser: Hoedemaeker, R.F. (Robert)
Kwast, Th.H. (Theo) van der
Boer, R. (Rob)
Koning, H.J. (Harry) de
Roobol-Bouts, M.J. (Monique)
Vis, A.N. (André)
Schröder, F.H. (Fritz)
Dokumenttyp: Artikel
Erscheinungsdatum: 2001
Schlagwörter: *Population Surveillance / Adenocarcinoma/*immunology/*pathology/prevention & control / Aged / Biopsy / Needle / Europe / Humans / Male / Mass Screening/*methods / Middle aged / Netherlands / Predictive Value of Tests / Prognosis / Prostate-Specific Antigen/*blood / Prostatic Neoplasms/*immunology/*pathology/prevention & control / Time Factors
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27608758
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://repub.eur.nl/pub/9698